MAGI3 Antibody

Acts as a scaffolding protein at cell-cell junctions, thereby regulating various cellular and signaling processes. Cooperates with PTEN to modulate the kinase activity of AKT1. Its interaction with PTPRB and tyrosine phosphorylated proteins suggests that it may link receptor tyrosine phosphatase with its substrates at the plasma membrane. In polarized epithelial cells, involved in efficient trafficking of TGFA to the cell surface. Regulates the ability of LPAR2 to activate ERK and RhoA pathways. Regulates the JNK signaling cascade via its interaction with FZD4 and VANGL2.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: ICC/IF, IP, WB.

Showing Publications 1 - 3 of 3.

Publications using NBP2-17210	Applications	Species
Elman JS, Ni TK, Mengwasser KE et al. Identification of FUBP1 as a Long Tail Cancer Driver and Widespread Regulator of Tumor Suppressor and Oncogene Alternative Splicing Cell Rep 2019-09-24 [PMID: 31553912] (WB, Human)	WB	Human
Ni TK, Elman JS, Jin DX et al. Premature polyadenylation of MAGI3 is associated with diminished N6-methyladenosine in its large internal exon Sci Rep 2018-01-23 [PMID: 29362392] (WB, Human)	WB	Human
Ni TK, Kuperwasser C. Premature polyadenylation of MAGI3 produces a dominantly-acting oncogene in human breast cancer. Elife. 2016-05-20 [PMID: 27205883] (ICC/IF, WB, IP, Human)	ICC/IF, WB, IP	Human

Array NBP2-17210

• MAGI3 Antibodies
• MAGI3 Lysate
• MAGI3 Protein